-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

From Detection to Development: A Regulatory Perspective on Measurable Residual Disease

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
Hematology Disease Topics & Pathways:
Research, Clinical trials, Hodgkin lymphoma, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Education, T Cell lymphoma, Diseases, Indolent lymphoma, Aggressive lymphoma, Treatment Considerations, Lymphoid Malignancies, Measurable Residual Disease
Monday, December 9, 2024, 10:30 AM-12:00 PM

Maryam Sarraf Yazdy, MD

(DHM2/CDER), Food and Drug Administration, Silver Spring

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>